Sitra Tauscher‐Wisniewski
Novartis (United States)(US)
Publications by Year
Research Areas
Neurogenetic and Muscular Disorders Research, RNA modifications and cancer, Treatment of Major Depression, Schizophrenia research and treatment, Attention Deficit Hyperactivity Disorder
Most-Cited Works
- → Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial(2021)456 cited
- → Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy(2020)286 cited
- → Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial(2022)275 cited
- → Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial(2022)260 cited
- → Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial(2021)241 cited
- → Fluoxetine and Adult Suicidality Revisited(2007)185 cited
- → Meta-Analysis of Suicide-Related Behavior Events in Patients Treated With Atomoxetine(2008)152 cited
- → Identification and validation of biomarkers for autism spectrum disorders(2015)140 cited
- → Brain Serotonin 5-HT1A Receptor Binding in Schizophrenia Measured by Positron Emission Tomography and [11C]WAY-100635(2002)133 cited
- → Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy(2021)112 cited